New Immune-Targeting drug surovatamig enters first human tests for arthritis and lupus
NCT ID NCT07201558
First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 4 times
Summary
This Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to know if it works, but the goal is to find a safe dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surovatamig
- What this could lead to
- If this early trial shows safety, it could lead to a new treatment option for rheumatoid arthritis and lupus by targeting specific immune cells.
- What could go wrong
- This is a very early Phase 1 study with only 48 participants, so it is primarily checking safety, not effectiveness. The drug may cause side effects or fail to work in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNBirmingham, Alabama, 35233, United States
-
Research Site
RECRUITINGFullerton, California, 92835, United States
-
Research Site
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
-
Research Site
RECRUITINGAllen, Texas, 75013, United States
-
Research Site
RECRUITINGMesquite, Texas, 75150, United States
-
Research Site
RECRUITINGBirtinya, 4575, Australia
-
Research Site
RECRUITINGClayton, 3168, Australia
-
Research Site
RECRUITINGEdegem, 2650, Belgium
-
Research Site
NOT_YET_RECRUITINGLeuven, 3000, Belgium
-
Research Site
RECRUITINGLiège, 4000, Belgium
-
Research Site
RECRUITINGMerksem (Antwerpen), 2170, Belgium
-
Research Site
NOT_YET_RECRUITINGPorto Alegre, 90035-903, Brazil
-
Research Site
NOT_YET_RECRUITINGSalvador, 41253-190, Brazil
-
Research Site
NOT_YET_RECRUITINGSão Paulo, 05652-900, Brazil
-
Research Site
RECRUITINGBeijing, 100034, China
-
Research Site
RECRUITINGChengdu, 610041, China
-
Research Site
RECRUITINGNanjing, 210008, China
-
Research Site
RECRUITINGBonn, 53127, Germany
-
Research Site
RECRUITINGJena, 07747, Germany
-
Research Site
NOT_YET_RECRUITINGMainz, 55131, Germany
-
Research Site
NOT_YET_RECRUITINGMünchen, D-80336, Germany
-
Research Site
NOT_YET_RECRUITINGMünster, 48149, Germany
-
Research Site
RECRUITINGBarcelona, 08025, Spain
-
Research Site
RECRUITINGCórdoba, 14004, Spain
-
Research Site
RECRUITINGMadrid, 28034, Spain
-
Research Site
RECRUITINGKaohsiung City, 83301, Taiwan
-
Research Site
RECRUITINGTaichung, 402, Taiwan
-
Research Site
RECRUITINGTaipei, 100, Taiwan
-
Research Site
RECRUITINGTaoyuan, 333, Taiwan
-
Research Site
RECRUITINGKyiv, 04050, Ukraine
-
Research Site
RECRUITINGTernopil, 46002, Ukraine
-
Research Site
RECRUITINGVinnytsia, 21018, Ukraine
-
Research Site
NOT_YET_RECRUITINGLondon, EC1M 6BQ, United Kingdom
-
Research Site
RECRUITINGLondon, SE1 9RT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a new biologic tame lupus flares?